<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164674">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01722097</url>
  </required_header>
  <id_info>
    <org_study_id>NMBDK2012</org_study_id>
    <secondary_id>2012-003787-51</secondary_id>
    <nct_id>NCT01722097</nct_id>
  </id_info>
  <brief_title>Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure</brief_title>
  <official_title>Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Denmark: The National Committee on Health Research Ethics</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study on laparoscopic hysterectomy is to investigate postoperative pain.
      Patients are allocated to either deep neuromuscular blockade and low intra-abdominal
      pressure (8 mmHg) or moderate neuromuscular blockade and usual intra-abdominal pressure (12
      mmHg).

      Primary hypothesis:

      Deep neuromuscular blockade and low intra-abdominal pressure (8 mmHg) reduces postoperative
      pain compared to moderate neuromuscular blockade and intra-abdominal pressure (12 mmHg).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Shoulder pain</measure>
    <time_frame>within 14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Occurrence of shoulder pain (evaluated on a VAS scale) or discomfort in the shoulder region within 14 days after operation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>within 4 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain (shoulder-, incisional-, abdominal - and overall pain) estimated as area under the curve from preoperatively till 4 days after operation Pain (shoulder-, incisional-, abdominal - and overall pain) estimated as area under the curve from preoperatively till 14 days after operation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient-movements</measure>
    <time_frame>During surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of unintended and unwanted patient-movements registered by the surgeon</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <condition>Pain</condition>
  <condition>Laparoscopy</condition>
  <arm_group>
    <arm_group_label>Deep neuromuscular blockade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Rocuronium Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h Other Name: Esmeron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate neuromuscular blockade</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Rocuronium Intravenous use: 0,3 mg/kg followed by NaCl-infusion Other Name: Esmeron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <arm_group_label>Deep neuromuscular blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Moderate neuromuscular blockade</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective laparoscopic hysterectomy (total/subtotal)

          -  Can read and understand Danish

          -  Informed consent

        Exclusion Criteria:

          -  BMI &gt; 30 kg/cm2

          -  Known allergy to medications that are included in the project

          -  Severe renal disease, defined by S-creatinine &gt; 0,200 mmol/L, GFR &lt; 30ml/min or
             hemodialysis)

          -  Neuromuscular disease that may interfere with neuromuscular data

          -  Lactating

          -  Impaired liver function

          -  Indication for rapid sequence induction (esophageal reflux/ hiatus hernia/other
             cause)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona Gätke, MD, ph.d.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of anesthesia, Herlev Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matias Vested Maden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of anesthesia, Herlev Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matias Vested Madsen, MD</last_name>
    <phone>+4538689058</phone>
    <email>matias.vested.madsen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mona Gätke, MD, ph.d</last_name>
    <phone>+4538682420</phone>
    <email>mona.gatke@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of anesthesia and department of minimal invasive gynecology, Aleris-Hamlet</name>
      <address>
        <city>Søborg</city>
        <zip>2830</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olav Istre, MD, DMSc, professor</last_name>
      <phone>+45 21277472</phone>
      <email>olav.istre@aleris-hamlet.dk</email>
    </contact>
    <investigator>
      <last_name>Matias Vested Madsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>November 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Matias Vested Madsen</investigator_full_name>
    <investigator_title>research assistent, MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
